Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison

Affiliations

• ¹ Sir Y.K. Pao Centre for Cancer and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong.
• ² Apellis Pharmaceuticals, Inc., 100 5th Avenue, Waltham, MA, 02451, USA.
• ³ Swedish Orphan Biovitrum AB, Tomtebodavägen 23a, Solna, 171 65, Stockholm, Sweden.
• ⁴ Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
• ⁵ Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA. Lynn.Huynh@analysisgroup.com.